{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:36:21Z","timestamp":1781238981906,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00392-023-02215-2","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T09:02:58Z","timestamp":1683190978000},"page":"991-1002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0918-6759","authenticated-orcid":false,"given":"Pedro E. P.","family":"Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago M. A.","family":"Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus R.","family":"Tofanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Gewehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C. P.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-3882","authenticated-orcid":false,"given":"Ana C.","family":"Sim\u00f5es e Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"issue":"10","key":"2215_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 341(10):709\u2013717. https:\/\/doi.org\/10.1056\/NEJM199909023411001","journal-title":"N Engl J Med."},{"issue":"23","key":"2215_CR2","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMOA010713","volume":"345","author":"J Ay","year":"2001","unstructured":"Ay J, Ohn NC, Ianni G et al (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23):1667\u20131675. https:\/\/doi.org\/10.1056\/NEJMOA010713","journal-title":"N Engl J Med"},{"key":"2215_CR3","doi-asserted-by":"publisher","unstructured":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429\u20131435. doi:https:\/\/doi.org\/10.1056\/NEJM198706043162301","DOI":"10.1056\/NEJM198706043162301"},{"issue":"11","key":"2215_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMOA1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 371(11):132\u2013133. https:\/\/doi.org\/10.1056\/NEJMOA1409077","journal-title":"N Engl J Med."},{"issue":"18","key":"2215_CR5","doi-asserted-by":"publisher","first-page":"E895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):E895\u2013E1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"issue":"36","key":"2215_CR6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/EURHEARTJ\/EHAB368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB368","journal-title":"Eur Heart J"},{"issue":"3","key":"2215_CR7","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1111\/J.1755-5922.2010.00258.X","volume":"30","author":"MA Raebel","year":"2012","unstructured":"Raebel MA (2012) Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 30(3):e156\u2013e166. https:\/\/doi.org\/10.1111\/J.1755-5922.2010.00258.X","journal-title":"Cardiovasc Ther"},{"issue":"3","key":"2215_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1056\/NEJME1414112\/SUPPL_FILE\/NEJME1414112_DISCLOSURES.PDF","volume":"372","author":"JR Ingelfinger","year":"2015","unstructured":"Ingelfinger JR (2015) A new era for the treatment of hyperkalemia? N Engl J Med 372(3):275\u2013277. https:\/\/doi.org\/10.1056\/NEJME1414112\/SUPPL_FILE\/NEJME1414112_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"2215_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004667","author":"JN Weiss","year":"2017","unstructured":"Weiss JN, Qu Z, Shivkumar K (2017) Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol. https:\/\/doi.org\/10.1161\/CIRCEP.116.004667","journal-title":"Circ Arrhythm Electrophysiol."},{"issue":"8","key":"2215_CR10","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/PHAR.1797","volume":"36","author":"KE Linder","year":"2016","unstructured":"Linder KE, Krawczynski MA, Laskey D (2016) Sodium zirconium cyclosilicate (ZS-9): a novel agent for the treatment of hyperkalemia. Pharmacotherapy 36(8):923\u2013933. https:\/\/doi.org\/10.1002\/PHAR.1797","journal-title":"Pharmacotherapy"},{"issue":"6","key":"2215_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/17512433.2020.1774363","volume":"13","author":"GB Colbert","year":"2020","unstructured":"Colbert GB, Patel D, Lerma EV (2020) Patiromer for the treatment of hyperkalemia. Expert Rev Clin Pharmacol. 13(6):563\u2013570. https:\/\/doi.org\/10.1080\/17512433.2020.1774363","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"1","key":"2215_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12882-022-02903-7","volume":"23","author":"K Kim","year":"2022","unstructured":"Kim K, Fagerstr\u00f6m J, Chen G, Lagunova Z, Furuland H, McEwan P (2022) Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden. BMC Nephrol 23(1):1\u201311. https:\/\/doi.org\/10.1186\/S12882-022-02903-7","journal-title":"BMC Nephrol"},{"key":"2215_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/JCM10235483","author":"A Montagnani","year":"2021","unstructured":"Montagnani A, Frasson S, Gussoni G, Manfellotto D (2021) Optimization of RAASi therapy with new potassium binders for patients with heart failure and hyperkalemia: rapid review and meta-analysis. J Clin Med. https:\/\/doi.org\/10.3390\/JCM10235483","journal-title":"J Clin Med"},{"key":"2215_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.N71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/BMJ.N71","journal-title":"BMJ"},{"key":"2215_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.L4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/BMJ.L4898","journal-title":"BMJ"},{"issue":"8","key":"2215_CR16","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/ejhf.1860","volume":"22","author":"P Rossignol","year":"2020","unstructured":"Rossignol P, Williams B, Mayo MR et al (2020) Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. Eur J Heart Fail 22(8):1462\u20131471. https:\/\/doi.org\/10.1002\/ejhf.1860","journal-title":"Eur J Heart Fail"},{"key":"2215_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac401","author":"J Butler","year":"2022","unstructured":"Butler J, Anker SD, Lund LH et al (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehac401. ((Butler J.; Siddiqi T.J.) Department of Medicine, University of Mississippi, Jackson, MS, United States)","journal-title":"Eur Heart J."},{"issue":"10","key":"2215_CR18","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"SD Anker","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F et al (2015) Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: Results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 17(10):1050\u20131056. https:\/\/doi.org\/10.1002\/ejhf.300","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"2215_CR19","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/ejhf.402","volume":"17","author":"B Pitt","year":"2015","unstructured":"Pitt B, Bakris GL, Bushinsky DA et al (2015) Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 17(10):1057\u20131065. https:\/\/doi.org\/10.1002\/ejhf.402","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2215_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ (2011) Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32(7):820\u2013828. https:\/\/doi.org\/10.1093\/eurheartj\/ehq502","journal-title":"Eur Heart J"},{"key":"2215_CR21","unstructured":"Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure\u2014Study Results\u2014ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03532009?term=prioritize+hf&draw=2&rank=1&view=results. Accessed 10 Aug 2022"},{"key":"2215_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/EHF2.14268","author":"JC Tardif","year":"2022","unstructured":"Tardif JC, Rouleau J, Chertow GM et al (2022) Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Fail. https:\/\/doi.org\/10.1002\/EHF2.14268","journal-title":"ESC Heart Fail"},{"issue":"5","key":"2215_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/1074248416629549","volume":"21","author":"L Li","year":"2016","unstructured":"Li L, Harrison SD, Cope MJ et al (2016) Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther 21(5):456\u2013465. https:\/\/doi.org\/10.1177\/1074248416629549","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"2215_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/S11897-022-00552-3","volume":"19","author":"D Murphy","year":"2022","unstructured":"Murphy D, Banerjee D (2022) Hyperkalaemia in heart failure: consequences for outcome and sequencing of therapy. Curr Heart Fail Rep 19(4):191. https:\/\/doi.org\/10.1007\/S11897-022-00552-3","journal-title":"Curr Heart Fail Rep"},{"issue":"1","key":"2215_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/J.KISU.2016.01.003","volume":"6","author":"VM Campese","year":"2016","unstructured":"Campese VM, Adenuga G (2016) Electrophysiological and clinical consequences of hyperkalemia. Kidney Int Suppl (2011). 6(1):16\u201319. https:\/\/doi.org\/10.1016\/J.KISU.2016.01.003","journal-title":"Kidney Int Suppl (2011)."},{"issue":"22","key":"2215_CR26","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/J.JACC.2020.04.021","volume":"75","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Butler J, Rossignol P et al (2020) Abnormalities of potassium in heart failure: JACC state-of-the-art review. J Am Coll Cardiol 75(22):2836\u20132850. https:\/\/doi.org\/10.1016\/J.JACC.2020.04.021","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2215_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/J.CARDFAIL.2018.03.002","volume":"24","author":"AS Desai","year":"2018","unstructured":"Desai AS, Liu J, Pfeffer MA et al (2018) Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail 24(5):313\u2013320. https:\/\/doi.org\/10.1016\/J.CARDFAIL.2018.03.002","journal-title":"J Card Fail"},{"issue":"5","key":"2215_CR28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/EJHF.1175","volume":"20","author":"LH Lund","year":"2018","unstructured":"Lund LH, Pitt B (2018) Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use. Eur J Heart Fail 20(5):931\u2013932. https:\/\/doi.org\/10.1002\/EJHF.1175","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2215_CR29","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/EJHF.1079","volume":"20","author":"JC Beusekamp","year":"2018","unstructured":"Beusekamp JC, Tromp J, van der Wal HH et al (2018) Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. Eur J Heart Fail 20(5):923\u2013930. https:\/\/doi.org\/10.1002\/EJHF.1079","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2215_CR30","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","volume":"67","author":"AR Chang","year":"2016","unstructured":"Chang AR, Sang Y, Leddy J et al (2016) Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension 67(6):1181\u20131188. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.07363","journal-title":"Hypertension"},{"issue":"9","key":"2215_CR31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/S40264-014-0196-1","volume":"37","author":"C Ben Salem","year":"2014","unstructured":"Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H (2014) Drug-induced hyperkalemia. Drug Saf 37(9):677\u2013692. https:\/\/doi.org\/10.1007\/S40264-014-0196-1","journal-title":"Drug Saf"},{"issue":"38","key":"2215_CR32","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1093\/EURHEARTJ\/EHX460","volume":"38","author":"M Aldahl","year":"2017","unstructured":"Aldahl M, Caroline Jensen AS, Davidsen L et al (2017) Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 38(38):2890\u20132896. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHX460","journal-title":"Eur Heart J"},{"issue":"2","key":"2215_CR33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/EHF2.12402","volume":"6","author":"C Linde","year":"2019","unstructured":"Linde C, Qin L, Bakhai A et al (2019) Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail 6(2):280\u2013290. https:\/\/doi.org\/10.1002\/EHF2.12402","journal-title":"ESC Heart Fail"},{"issue":"8","key":"2215_CR34","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/EJHF.1757","volume":"22","author":"LB Cooper","year":"2020","unstructured":"Cooper LB, Benson L, Mentz RJ et al (2020) Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. Eur J Heart Fail 22(8):1390\u20131398. https:\/\/doi.org\/10.1002\/EJHF.1757","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2215_CR35","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/KI.1985.229","volume":"28","author":"RL Tannen","year":"1985","unstructured":"Tannen RL (1985) Diuretic-induced hypokalemia. Kidney Int 28(6):988\u20131000. https:\/\/doi.org\/10.1038\/KI.1985.229","journal-title":"Kidney Int"},{"issue":"6","key":"2215_CR36","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/EJHF.688","volume":"19","author":"P Rossignol","year":"2017","unstructured":"Rossignol P, Girerd N, Bakris G et al (2017) Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail 19(6):792\u2013799. https:\/\/doi.org\/10.1002\/EJHF.688","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"2215_CR37","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1001\/JAMA.2015.11904","volume":"314","author":"LB Cooper","year":"2015","unstructured":"Cooper LB, Hammill BG, Peterson ED et al (2015) Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA 314(18):1973. https:\/\/doi.org\/10.1001\/JAMA.2015.11904","journal-title":"JAMA"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02215-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02215-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02215-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T19:04:30Z","timestamp":1687806270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02215-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2215"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02215-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"27 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors report no relationships that could be construed as a conflict of interest. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}